Business Wire

LUNDBECK-FOUNDATION

5.3.2024 16:31:25 CET | Business Wire | Press release

Share
Pioneering work in computational and theoretical neuroscience is awarded the world’s largest brain research prize

The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience. This year’s award recognizes the pioneering work of three leading neuroscientists – Professor Larry Abbott at Columbia University (USA), Professor Terrence Sejnowski at the Salk Institute (USA), and Professor Haim Sompolinsky at Harvard University (USA) and the Hebrew University (Israel).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305504553/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Credit: The Lundbeck Foundation

Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance. The winners of The Brain Prize 2024 have made pioneering contributions to these scientific areas by uncovering some of the principles that govern the brain’s structure, function, and the emergence of cognition and behaviour.

The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.

Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:

It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience. The three scientists have applied novel and sophisticated approaches from physics, mathematics, and statistics to study the brain. They have developed vital tools for the analysis of highly complex datasets acquired by modern day experimental neuroscientists.

The three prize winners have also proposed conceptual frameworks for understanding some of the brain’s most fundamental processes such as learning, memory, perception and how the brain generates maps of the external world. They have also provided crucial new insights into what may go awry in several devastating disorders of the nervous system, such as epilepsy, Alzheimer’s disease, and schizophrenia. In addition, their scientific achievements have paved the way for the development of brain-inspired artificial intelligence, one of the emerging and transformational technologies of our time.

On behalf of the Lundbeck Foundation, CEO Lene Skole extends her warmest congratulations to each of the three Brain Prize recipients:

Their pioneering research has created trailblazing knowledge and paved the way for other scientists to better understand critical brain functions, also in relation to diseases. It aligns fully with our purpose of bringing discoveries to lives. Each of their scientific endeavours began in the 70’s, and their determination, courage and persistence over decades should serve as inspiration for other scientists, and indeed be rewarded.”

FACTS

The human brain consists of approximately 100 billion neurons connected by trillions of synaptic connections. Every function the brain performs relies on the flow of information through these staggeringly complex networks of neurons. A fundamental goal of neuroscience is to understand how these networks are wired together, and how the patterns of neural activity within them give rise to cognition and behaviour. The sheer complexity of the brain means that understanding its language requires theoretical and computational approaches.

Theoretical and computational neuroscience uses mathematics, computer science, theoretical analysis, and abstractions of the brain to understand the principles that govern its structure, how it processes information, generates behaviour, and gives rise to cognitive abilities as perception, imagination, intelligence, the formation of knowledge, memory, problem-solving, decision-making, and the production of language. The field has laid the foundations for the development of AI - one of the most revolutionary developments in modern science.

MORE INFO

Find out more – see the information pack of The Brain Prize 2024 >>

About The Brain Prize

The Brain Prize is the world’s largest neuroscience research prize, and it is awarded each year by the Lundbeck Foundation. The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research. Recipients of The Brain Prize may be of any nationality and work in any country in the world. Since it was first awarded in 2011, The Brain Prize has been awarded to 47 scientists from 10 ten different countries. The Brain Prize recipients are presented with their award by His Royal Highness, King Frederik of Denmark, at a ceremony in the Danish capital, Copenhagen.

About the Lundbeck Foundation

The Lundbeck Foundation is an enterprise foundation encompassing a comprehensive range of commercial and philanthropic activities – all united by its strong purpose; Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner of several international healthcare and medtech companies – Lundbeck, Falck, ALK, Ellab, and Ferrosan Medical Devices – and an active investor in business, science and people through its commercial investments in the financial markets; in biotech companies based on Danish research and through philanthropic grants to science talents and programmes in Danish universities. The Foundation’s philanthropic grants amount to more than DKK 500m annually primarily focusing on the brain – including the world’s largest personal prize awarded in neuroscience, The Brain Prize.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305504553/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release

Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh

Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release

Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye